EU data protection regulation – harming cancer research

DAVID J KERR

The European Union (EU) has undertaken a review of data confidentiality and data protection given the extraordinary advances that have been made in transnational electronic data transfer and the potential for data sharing to infringe on an individual’s rights to privacy. The current EU Data Protection Directive (95/46/EC) did not consider important technological developments, such as social networks and cloud computing; therefore, legislators determined that new guidelines are required and have proposed an amendment in the form of the General Data Protection Regulation (GDPR).

Paolo Casali has produced a position paper on the EU GDPR, endorsed by Europe’s leading cancer research organisations, in response to anxieties induced by the wording of one of the amendments (191 to Article 81) to the GDPR. The amendment could be interpreted as imposing the requirement for researchers to ask for a patient’s ‘specific’ consent every single time new research is carried out on already available data and/or tissues.

One of the traditional strengths of European cancer research has been the quality, depth and coverage of its cancer registries, which offers the potential to link demographic, clinical and genetic data to explore phenotype-genotype correlations. The Northern European registries in particular have made consistent and important contributions to the international literature on epidemiology and outcome studies. These resources are all predicated on convention and the societal urge to share knowledge, and ultimately wisdom, so data can be pooled and can contribute to ‘big science’. The identity of individuals is anonymised and is, therefore, protected; nevertheless, when asked directly, the vast majority of patients with cancer are keen to contribute in any way they can to the wider research agenda.

The cancer community is deeply concerned about the unintended consequences of the current wording of the European Union (EU) draft Regulation on Data Protection, which may challenge the survival of retrospective clinical research, biobanking, and population-based cancer registries in the EU. This directive could negatively affect Europe’s competitiveness in cancer research.
Consent would also be required for the recording of data in population-based disease registries, which by definition need be all-inclusive—that is, collection of all of the data for all individuals belonging to a given population is mandatory if the information is to be truly reflective.

All of us in medicine understand the need for confidentiality and data protection, but this legislation could have a far-reaching set of unintended consequences. Apart from deconstructing world leading cancer registries, it will place an enormous barrier to translational cancer research. In Oxford, the cancer trials office has led the UK’s adjuvant colorectal cancer trials portfolio for the past 15 years, generating a bioresource comprising 5,000 to 6,000 germline DNA and tissue samples that have been pseudo-anonymised and linked to the trials databases. Such a resource enables clinically relevant outcomes, such as survival and toxicity, to be captured. This repository has proven to be an immensely powerful biobank, which has been used in international collaborations across four continents, providing insights into the genetics and biology of colorectal cancer susceptibility, prognosis, and genesis of chemotherapy-induced toxicity.

All samples were gifted by patients that have died; thus, such patients are of course beyond the means of re-consent. This biobank could potentially be rendered redundant by the proposed amendment to the Data Protection Directive, which would create a significant practical barrier to the development of companion diagnostics for novel anticancer drugs. Companion diagnostics or predictive markers are often validated in so-called retrospective-prospective studies, whereby a prospective trial of the relevant anticancer drug and associated biobank are interrogated at some interval after the trial has closed, to explore the relationship of some new marker with drug efficacy or toxicity. Having to regain consent from every patient every time researchers want to test a new hypothesis, using a biomarker that might not even have been on the horizon when the trial was performed, places an impossible burden of care on the research team and runs counter to the initial gift made by the patient. Of course we must put in place a legislative framework that protects data confidentiality, allied to transparent mechanisms to oversee retrospective research projects (for example, the Local Research Ethics Committee or Institutional Review Board) and storage of patient tissue in biobanks, but most EU Member States have existing laws that function perfectly well in this regard.

Casali finishes his article with a strong plea, and one which I echo, “The European cancer community urges all EU decision makers to save research, as well as to protect the right of patients to donate their data and tissues to advance research and find cures. EU decision makers are urged to change the European Parliament Amendments 191 and 194 to Articles 81 and 83, as they would impair public health research within and across EU Member States.”

**References**

4. D Rosmarin et al. (2014) Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. JCO 32:1091–39
8. P Quirke et al. (2011) Value of mismatch repair, KRAS and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. JCO 29:1261–1270

**Author affiliations**

Department of Medicine, Nuffield Division of Clinical Laboratory Sciences, John Radcliffe Infirmary, Oxford, UK